(Q35558574)

English

Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group

scientific article published on November 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 August 2017

Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group (English)

1 reference

Europe PubMed Central

8 August 2017

phase II clinical trial

0 references

1 reference

10.1016/S0959-8049(03)00629-4

https://api.crossref.org/works/10.1016/S0959-8049(03)00629-4

21 March 2024

7

object named as

J. L. Raoul

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556925

21 March 2024

author name string

E. Briasoulis

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556925

21 March 2024

N. Pavlidis

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556925

21 March 2024

C. Terret

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556925

21 March 2024

J. Bauer

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556925

21 March 2024

W. Fiedler

5

0000-0003-0275-8803

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556925

21 March 2024

P. Schöffski

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556925

21 March 2024

D. Hess

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556925

21 March 2024

R. Selvais

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556925

21 March 2024

D. Lacombe

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556925

21 March 2024

P. Bachmann

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556925

21 March 2024

P. Fumoleau

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556925

21 March 2024

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14556925

21 March 2024

publication date

1 November 2003

1 reference

Europe PubMed Central

8 August 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0959804903006294?httpAccept=text/xml

1 reference

10.1016/S0959-8049(03)00629-4

https://api.crossref.org/works/10.1016/S0959-8049(03)00629-4

21 March 2024

https://api.elsevier.com/content/article/PII:S0959804903006294?httpAccept=text/plain

1 reference

10.1016/S0959-8049(03)00629-4

https://api.crossref.org/works/10.1016/S0959-8049(03)00629-4

21 March 2024

European Journal of Cancer

1 reference

Europe PubMed Central

8 August 2017

39

1 reference

Europe PubMed Central

8 August 2017

16

1 reference

Europe PubMed Central

8 August 2017

2334-2340

1 reference

Europe PubMed Central

8 August 2017

Trends in pancreatic cancer mortality in Europe, 1955–1989

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer of the pancreas. 50 years of surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

No standard treatment is available for advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

D-19575--a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of cisplatin in adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900629-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(03)00629-4

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35558574&oldid=2107397993"